Addiction Rehab: A Review of “Breaking the Cycle: Free Yourself From Sex Addiction, Porn Addiction, and Shame” by George N. Collins (With Andrew Adelman). Oakland, CA: New Harbinger Publications, 2010. 212 Pages, $17.95 (Paperback), $9.99 (E-Book).
A Review of “Breaking the Cycle: Free Yourself from Sex Addiction, Porn Addiction, and Shame” by George N. Collins (with Andrew Adelman). Oakland, CA: New Harbinger Publications, 2010. 212 pages, .95 (paperback), .99 (e-book).
Filed under: Addiction Rehab
J Sex Marital Ther. 2013 Mar; 39(2): 193-4
Herring B
Is there an optimal factor structure of the Positive and Negative Syndrome Scale in patients with first-episode psychosis?
Filed under: Addiction Rehab
Scand J Psychol. 2012 Dec 18;
Langeveld J, Andreassen OA, Auestad B, Faerden A, Hauge LJ, Joa I, Johannessen JO, Melle I, Rund BR, Røssberg JI, Simonsen E, Vaglum P, Larsen TK
Langeveld, J., Andreassen, O. A., Auestad, B., Faerden, A., Hauge, L. J., Joa, I., Johannessen, J. O., Melle, I., Rund, B. R., Røssberg, J. I., Simonsen, E., Vaglum, P. & Larsen, T. K. (2012). Is there an optimal factor structure of the Positive and Negative Syndrome Scale in patients with first-episode psychosis? Scandinavian Journal of Psychology. The Positive and Negative Syndrome Scale (PANSS) is the most widely used scale to assess a variety of symptoms in patients with schizophrenia and other psychoses. The factor structure of the PANSS has been examined with confirmatory factor analyses in several studies, but not in a well-defined first-episode psychosis sample. The aim of this paper is to examine the statistical fit of five different PANSS models in a first-episode, non-affective psychosis sample. Confirmatory factor analyses were performed on PANSS data (n?=?588). A main criterion for best fit was defined as the Expected Cross Validation Index (ECVI). No tested model revealed an optimally satisfactory model fit index. The Wallwork/Fortgang five-factor model demonstrated the most optimal psychometric properties. The corresponding subscales of all evaluated five-factor models were strongly intercorrelated. The Wallwork/Fortgang five-factor model was found to be statistically and clinically ideal among patients with first-episode psychosis. Therefore, we recommend this model in forthcoming studies among patients with first-episode psychosis. However, to prevent the loss of clinically valuable information on an item level, we do not recommend removing any items from the original form. Our study also implies that the specific choice of model will not have a substantial effect on outcome results in studies on the course and outcome in first-episode psychosis.
HubMed – addiction
Therapeutic advances in the treatment of nicotine addiction: present and future.
Filed under: Addiction Rehab
Ther Adv Chronic Dis. 2010 May; 1(3): 95-106
Casella G, Caponnetto P, Polosa R
While the proportion of the adult population that smokes has declined steadily in several westernized societies, the rate of successful quit attempts is still low. This is because smokers develop nicotine dependence, a powerful addiction that may require multiple attempts and long-term treatment to achieve enduring abstinence. Currently available first-line agents for smoking cessation therapy include nicotine replacement therapy (available in several formulations, including transdermal patch, gum, nasal spray, inhaler, and lozenge), bupropion (an atypical antidepressant), and varenicline (a partial agonist of the ?4?2 nicotinic acetylcholine receptor that was recently developed and approved specifically for smoking cessation therapy). Second-line agents are nortriptyline (a tricyclic antidepressant agent) and the antihypertensive agent clonidine. With the exception of varenicline, which has been shown to offer significant improvement in abstinence rates over bupropion, all of the available treatments appear similarly effective. The adverse event profiles of nortriptyline and clonidine make them more appropriate for second-line therapy, when first-line treatments have failed or are not tolerated. However, the currently marketed smoking cessation drugs reportedly lack high levels of efficacy, particularly in real-life settings. New medications and vaccines with significant clinical advantage are now in the advanced stage of development and offer promise. These include nicotine vaccines and monoamine type B inhibitors. In this review article we discuss current and emerging pharmacotherapies for tobacco dependence focusing on their mechanisms of action, efficacy and adverse event profiles.
HubMed – addiction
More Addiction Rehab Information…